|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
The significance of PTHrP in cancer is not confined to malignancy-associated hypercalcemia, and sufficient evidence now also supports its role in skeletal metastasis through its modulation of bone turnover.
|
31576548 |
2019 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Parathyroid hormone (PTH)-related protein (PTHrP) (gene name Pthlh) was discovered as the factor responsible for the humoral hypercalcemia of malignancy.
|
31476292 |
2019 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
In case one, the serum levels and immunostaining for parathyroid hormone-related protein (PTHrP) verified humoral hypercalcemia of malignancy (HHM).
|
29951343 |
2018 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Parathyroid hormone (PTH) is the most important regulator of the concentrations of calcium and phosphate in blood; parathyroid hormone-related protein (PTHrP) was the most frequent cause of humoral hypercalcemia of malignancy; parathyroid hormone 1 receptor (PTH1R) is the common receptor for PTH and PTHrP.
|
29278884 |
2018 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Parathyroid hormone-related protein (PTHrP) that causes hypercalcemia of malignancy appears to function as an endogenous smooth muscle relaxant.
|
28656682 |
2017 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Assessment demonstrated suppressed parathyroid hormone and 1,25-dihydroxyvitamin D levels with elevated circulating levels of parathyroid hormone related protein, indicating the diagnosis of humoral hypercalcemia of malignancy (HHM).
|
28371408 |
2017 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report a case of metastatic breast cancer with parathyroid hormone-related protein associated with hypercalcemia of malignancy that was treated with transarterial embolization of the hepatic metastatic lesions.
|
28178714 |
2017 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
PTHrP, a mediator of humoral hypercalcemia of malignancy, is considered as a potential activator to induce breast cancer cells metastasizing to bone.
|
20401668 |
2011 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of PTHLH and high levels of circulating IL6 in OCCA patients may explain the frequent occurrence of hypercalcemia of malignancy and thromboembolic events in OCCA.
|
21343371 |
2011 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because lung cancer patients who frequently develop HHM and PTHrP expression in lung cancer has been only partially explained, the significance of our findings indicates that CaR variants may provide a positive feedback between PTHrP and calcium and result in the syndrome of HHM.
|
21532883 |
2011 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PTHrP's dysregulated expression has traditionally been associated with oncogenic pathologies as the major causative agent of malignancy-associated hypercalcemia, but recent evidence revealed a driving role in skeletal metastasis progression.
|
21901625 |
2011 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PTHrP is also associated with the progression of skeletal metastases, and its dysregulated expression in advanced cancers causes malignancy-associated hypercalcemia.
|
22056386 |
2011 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We suggest that HIF-2 induced by intratumoral hypoxia or by other genetic alterations may contribute to the pathogenesis of hypercalcemia of malignancy and cancer aggressiveness by stimulation of PTHrP expression.
|
20890122 |
2010 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, ectopic expression of EGFR in a receptor-low but AREG-expressing cell line increased PTHrP mRNA levels in vitro, and induced the capability to cause HHM and rapid osteolytic growth in vivo.
|
19825997 |
2009 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Such neutralizing antibodies against PTHrP are therapeutically effective in animal models of the humoral hypercalcemia of malignancy and of bone metastasis formation.
|
19346515 |
2009 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The high levels of plasma PTHrP and the demonstrated predominant renal mechanism in this case of HCM are suspected to be the cause for its refractoriness to bone resorption inhibitors.
|
17188588 |
2007 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Parathyroid hormone-related protein (PTHrP) and macrophage inflammatory protein-1 alpha (MIP-1 alpha) are important factors in the pathogenesis of HHM in ATLL and the expression of PTHrP can be activated by nuclear factor kappaB (NF-kappaB).
|
18089816 |
2007 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We previously showed that ATLL cells constitutively express high levels of PTHrP via activation of promoters P2 and P3, resulting in HHM.
|
17554373 |
2007 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to evaluate the role of the epidermal growth factor receptor (EGFR) in parathyroid hormone-related protein (PTHrP) expression and humoral hypercalcaemia of malignancy (HHM), using two different human squamous-cell carcinoma (SCC) xenograft models.
|
17533397 |
2007 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
PTHrP appears as the major causative agent in humoral hypercalcemia of malignancy (HHM) associated to a broad range of tumors.
|
16223565 |
2006 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
An ovarian clear cell carcinoma induced PTHrP-related HHM, which resulted from the high expression of all isoforms for PTHrP gene.
|
16956653 |
2006 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Parathyroid hormone-related protein (PTHrP) plays a primary role in the development of humoral hypercalcemia of malignancy seen in the majority of adult T-cell leukemia/lymphoma (ATLL) patients with human T-cell lymphotropic virus type-1 (HTLV-1) infection.
|
15889157 |
2005 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although originally discovered as the peptide responsible for humoral hypercalcemia of malignancy (HHM), parathyroid hormone-related protein (PTHrP) has been shown to play a major role in fetal development.
|
15831076 |
2005 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Parathyroid hormone-related protein (PTHrP) came to the attention of the scientific community in the mid-1980s because of its association with the paraneoplastic syndrome of humoral hypercalcemia of malignancy.
|
16022632 |
2005 |
|
Humoral hypercalcemia of malignancy (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, humanized anti-PTHrP may be useful for the treatment of the humoral hypercalcemia of malignancy in humans.
|
15517871 |
2004 |